Royalty Pharma Announces R&D Funding Collaboration With Biogen
Portfolio Pulse from
Royalty Pharma has announced a collaboration with Biogen, providing up to $250 million in R&D funding for Biogen's litifilimab, a biologic in Phase 3 development for lupus treatment.
February 12, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen receives up to $250 million in R&D funding from Royalty Pharma for its lupus treatment, litifilimab, currently in Phase 3 development.
The funding from Royalty Pharma provides significant financial support for Biogen's development of litifilimab, potentially accelerating its progress and enhancing Biogen's pipeline. This is likely to be viewed positively by investors, potentially boosting Biogen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90